We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+57.69%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$287M
AUM Growth
+$64.2M
Cap. Flow
-$25.8M
Cap. Flow %
-9%
Top 10 Hldgs %
99.16%
Holding
12
New
–
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ENGN icon
enGene Therapeutics
ENGN
+$2.8M

Top Sells

Rank Stock Value
1
BBNX
Beta Bionics
BBNX
+$16.1M
2
KMTS
Kestra Medical Technologies
KMTS
+$7.01M
3
NUVB icon
Nuvation Bio
NUVB
+$4.65M
4
UPB
Upstream Bio Inc
UPB
+$747K
5
ENGNW icon
enGene Therapeutics Warrants
ENGNW
+$63.4K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$72.4M 25.27%
8,081,089
-750,000
-8% -$4.65M
BBOT
2
BridgeBio Oncology
BBOT
$707M
$41.2M 14.37%
3,289,661
– –
BBNX
3
Beta Bionics
BBNX
$706M
$40.1M 14%
1,316,183
-603,942
-31% -$16.1M
BCAX
4
Bicara Therapeutics
BCAX
$1.78B
$37.1M 12.95%
2,204,650
– –
KMTS
5
Kestra Medical Technologies
KMTS
$1.23B
$36.4M 12.71%
1,373,591
-272,302
-17% -$7.01M
UPB
6
Upstream Bio Inc
UPB
$349M
$36M 12.57%
1,326,293
-30,000
-2% -$747K
ENGN icon
7
enGene Therapeutics
ENGN
$122M
$7.91M 2.76%
876,357
+350,000
+66% +$2.8M
ALMS
8
Alumis Inc
ALMS
$3.57B
$6.38M 2.23%
653,223
– –
SANA icon
9
Sana Biotechnology
SANA
$885M
$3.43M 1.2%
843,750
– –
IMA
10
ImageneBio Inc
IMA
$63.1M
$3.14M 1.1%
455,361
– –
REPL icon
11
Replimune Group
REPL
$814M
$2.42M 0.84%
248,672
– –
ENGNW icon
12
enGene Therapeutics Warrants
ENGNW
$3.75M
– –
-89,702
Closed -$63.4K

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, Omega Fund Management held 12 positions worth $287M, up 29% from $222M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Omega Fund Management withdrew a net $25.8M in Q4 2025, closing 1 position and reducing 4 holdings. Its most notable exit was enGene Therapeutics Warrants, an estimated $63.4K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Omega Fund Management added an estimated $2.8M to enGene Therapeutics.

  • Omega Fund Management added most to enGene Therapeutics in Q4 2025, an estimated $2.8M increase.
  • Omega Fund Management's biggest Q4 2025 reduction was Beta Bionics, cutting an estimated $16.1M.
  • Omega Fund Management fully exited enGene Therapeutics Warrants in Q4 2025, selling an estimated $63.4K.
  • Omega Fund Management's ten largest holdings make up 99% of its $287M portfolio in Q4 2025.
  • Omega Fund Management opened 0 new positions and closed 1 in Q4 2025.
  • Omega Fund Management's portfolio value rose 29% quarter-over-quarter to $287M.

Based on Omega Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.